Cingulate NDA Resubmit Set for Dec 2026 as Cash Hits $23.2M

Cingulate Inc. (NASDAQ: CING) said on 13 November 2026 that it has substantially completed the manufacturing work needed to answer the U.S. Food and Drug Administration's chemistry, manufacturing and controls questions on its lead ADHD candidate CTx-1301, and that it expects to resubmit the new drug application between December 2026 and January 2027. The company reported $23.2 million in cash and cash equivalents as of 30 September 2026, up from $10.95 million at 31 December 2025, and working capital of $18.8 million versus $1.7 million at the prior year-end.

Context — why the CTx-1301 refiling matters now

The FDA issued a Complete Response Letter for the CTx-1301 NDA on 1 June 2026, following an October 2025 acceptance of the filing and a 31 May 2026 PDUFA target action date. The CRL asked for additional CMC information and, the company said, raised no concerns about the clinical safety or efficacy of the asset.

That distinction frames the entire refiling. A CMC-only CRL is a documentation and process question rather than a clinical one, so the path back to the agency runs through manufacturing records and analytical data rather than new patient trials. Cingulate and its contract development and manufacturing organization, Bend Bioscience, have been working through that package since June.

The company's prior-period comparison is the CRL itself: before June, the NDA sat under active review with a defined action date. After June, the clock stopped and the burden shifted to the company to produce the missing information. The refiling is the point at which that clock restarts.

Macro conditions are not the driver here. This is a single-asset regulatory story where the relevant variables are agency classification and the company's cash runway, not rates or index levels. Cingulate does not disclose the size of the CMC information request, the cost of the remaining documentation work, or the specific manufacturing deficiencies cited, so the scope of what remains is not public.

What changed to trigger the update now is completion of the underlying manufacturing work. Chairman and CEO Shane J. Schaffer said the company is finalizing data and documentation and expects to resubmit by January 2027, potentially sooner. That is a company expectation, not an agency commitment.

Data — what the numbers show

The balance sheet moved sharply in nine months. Cash rose to $23.2 million from $10.95 million, total assets to $28.15 million from $15.07 million, and total liabilities fell to $7.38 million from $12.56 million. Total stockholders' equity climbed to $20.77 million from $2.51 million.

Metric	30 Sep 2026	31 Dec 2025
Cash and equivalents	$23.2M	$11.0M
Total assets	$28.2M	$15.1M
Total liabilities	$7.4M	$12.6M
Working capital	$18.8M	$1.7M
Accumulated deficit	$155.3M	$132.4M

The cash build came from financing, not operations. Cingulate raised $12.0 million in a first-quarter private placement and $22.5 million through an at-the-market agreement with AGP and a purchase agreement with Lincoln Park Capital, offset by $20.4 million of cash used in operations. The accumulated deficit widened to $155.3 million from $132.4 million.

Operating expenses diverged. Third-quarter research and development was $2.91 million, up 2.2% from $2.85 million a year earlier, as higher drug manufacturing costs tied to the CRL offset lower clinical and regulatory spend. Nine-month R&D fell 15.3% to $6.58 million from $7.77 million. Selling, general and administrative expense rose 45.5% in the quarter to $4.58 million and 116.6% over nine months to $14.25 million, driven by commercial readiness build-out through commercialization partner Indegene.

Net loss was $7.73 million for the quarter versus $7.34 million a year earlier, and $22.91 million for nine months versus $16.18 million. The company believes its cash funds operations into mid-2027, including regulatory approval costs for CTx-1301.

Analysis — what it means for markets and tickers

The setup is a binary regulatory catalyst with a financing overhang. Cingulate has funded itself through equity-linked facilities, and the accumulated deficit shows the cumulative cost of getting one asset to the agency. Every month of delay pushes the commercial launch further out while SG&A for commercial readiness keeps running, which is the structural tension in the numbers: the company is spending to be ready to sell a product it cannot yet sell.

Second-order effects land on the small-cap biotech cohort with single lead assets and CMC-driven CRLs, and on the ADHD treatment space, where the company cites roughly 100 million annual U.S. prescriptions and more than 20 million diagnosed patients. Approval would put a new once-daily dexmethylphenidate formulation into that market. Failure or further delay would leave the pipeline dependent on earlier-stage PTR-based candidates.

The counter-argument worth weighing: the CRL did not touch safety or efficacy, which the company emphasizes, but a CMC CRL can still require substantial rework, and the report gives no detail on how much documentation remains. The company's own language includes the caveat that there can be no assurance regarding the timing of any resubmission or whether approval will occur.

Positioning follows the calendar. Holders are effectively long a December-to-January refiling event, and the equity raises through AGP and Lincoln Park mean supply has been part of the tape. The stock is a single-catalyst name where flow concentrates around FDA news rather than fundamentals.

Outlook — what to watch next

The near-term catalyst is the NDA resubmission itself, expected between December 2026 and January 2027. Once the FDA receives it, the agency is expected to classify it as a Class 1 or Class 2 resubmission, carrying review goals of two and six months respectively — so the classification, not the refiling date, sets the next decision window.

A second item is the cash position. The company guides to funding into mid-2027, which brackets the expected review period but leaves little margin if the agency extends its review or issues a second CRL. Any additional capital raise would be the signal to watch.

A third is commercial build-out spending. SG&A has more than doubled year over year, and the pace of that spend against a pre-revenue product is the clearest read on management's confidence in the timeline.

Frequently Asked Questions

What does a Complete Response Letter mean for a drug application?

A Complete Response Letter is the FDA's way of declining to approve an application in its current form, typically listing what the sponsor must address before a refiling can be reviewed. Cingulate's CRL, issued 1 June 2026, requested additional CMC information and did not raise clinical safety or efficacy concerns. The application is not rejected outright; the company must fix the identified gaps and resubmit.

How long will the FDA take to review the resubmitted NDA?

That depends on how the agency classifies the resubmission. Cingulate said it expects a Class 1 or Class 2 designation, which carry review goals of two months and six months respectively. The company has not said which class it anticipates, and the classification is the FDA's determination, not the company's. The refiling is expected between December 2026 and January 2027.

How is Cingulate funding operations while the NDA is pending?

The company ended September 2026 with $23.2 million in cash and $18.8 million in working capital, after raising $12.0 million in a first-quarter private placement and $22.5 million through at-the-market and purchase agreements. It used $20.4 million in operations over nine months. Management said this funds operations into mid-2027, covering CTx-1301 regulatory costs and commercial readiness.

Bottom Line

Cingulate has the manufacturing work done and the cash to reach mid-2027, but the NDA's fate now rests on an FDA classification it does not control.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.